-DOCSTART- -X- O
Using -X- _ O
a -X- _ O
viral -X- _ O
model -X- _ O
of -X- _ O
the -X- _ O
demyelinating -X- _ B-Patient
disease -X- _ I-Patient
multiple -X- _ I-Patient
sclerosis -X- _ I-Patient
( -X- _ I-Patient
MS -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
intraspinal -X- _ B-Intervention
transplantation -X- _ I-Intervention
of -X- _ I-Intervention
human -X- _ I-Intervention
embryonic -X- _ I-Intervention
stem -X- _ I-Intervention
cell-derived -X- _ I-Intervention
neural -X- _ I-Intervention
precursor -X- _ I-Intervention
cells -X- _ I-Intervention
( -X- _ I-Intervention
hNPCs -X- _ I-Intervention
) -X- _ I-Intervention
results -X- _ B-Outcome
in -X- _ I-Outcome
sustained -X- _ I-Outcome
clinical -X- _ I-Outcome
recovery -X- _ I-Outcome
, -X- _ O
although -X- _ O
hNPCs -X- _ O
were -X- _ O
not -X- _ O
detectable -X- _ O
beyond -X- _ O
day -X- _ O
8 -X- _ O
posttransplantation. -X- _ O
Improved -X- _ B-Outcome
motor -X- _ I-Outcome
skills -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
neuroinflammation -X- _ I-Outcome
, -X- _ I-Outcome
decreased -X- _ I-Outcome
demyelination -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
enhanced -X- _ I-Outcome
remyelination. -X- _ I-Outcome
Evidence -X- _ O
indicates -X- _ O
that -X- _ O
the -X- _ O
reduced -X- _ B-Outcome
neuroinflammation -X- _ I-Outcome
is -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
increased -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
CD25 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
FOXP3 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
regulatory -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
( -X- _ I-Outcome
Tregs -X- _ I-Outcome
) -X- _ I-Outcome
within -X- _ I-Outcome
the -X- _ I-Outcome
spinal -X- _ I-Outcome
cords. -X- _ I-Outcome
Coculture -X- _ I-Outcome
of -X- _ I-Outcome
hNPCs -X- _ I-Outcome
with -X- _ I-Outcome
activated -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
reduced -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
proliferation -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
Treg -X- _ I-Outcome
numbers. -X- _ I-Outcome
The -X- _ O
hNPCs -X- _ O
acted -X- _ O
, -X- _ O
in -X- _ O
part -X- _ O
, -X- _ O
through -X- _ O
secretion -X- _ O
of -X- _ O
TGF-β1 -X- _ O
and -X- _ O
TGF-β2. -X- _ O
These -X- _ O
findings -X- _ O
indicate -X- _ O
that -X- _ O
the -X- _ O
transient -X- _ O
presence -X- _ O
of -X- _ O
hNPCs -X- _ O
transplanted -X- _ O
in -X- _ O
an -X- _ O
animal -X- _ O
model -X- _ O
of -X- _ O
MS -X- _ O
has -X- _ O
powerful -X- _ O
immunomodulatory -X- _ O
effects -X- _ O
and -X- _ O
mediates -X- _ O
recovery. -X- _ O
Further -X- _ O
investigation -X- _ O
of -X- _ O
the -X- _ O
restorative -X- _ O
effects -X- _ O
of -X- _ O
hNPC -X- _ O
transplantation -X- _ O
may -X- _ O
aid -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
clinically -X- _ O
relevant -X- _ O
MS -X- _ O
treatments -X- _ O
. -X- _ O

